149 related articles for article (PubMed ID: 21387600)
1. [Molecular target therapy for colorectal cancer].
Uetake H; Ishikawa T; Sugihara K
Nihon Geka Gakkai Zasshi; 2011 Jan; 112(1):39-42. PubMed ID: 21387600
[No Abstract] [Full Text] [Related]
2. [Efficacy of monoclonal antibodies in combination with chemotherapy in metastatic colorectal cancer].
Takiuchi H
Nihon Rinsho; 2011 Apr; 69 Suppl 3():459-63. PubMed ID: 22214004
[No Abstract] [Full Text] [Related]
3. [Pharmacoeconomics of molecular target drug: K-ras testing and cetuximab for colorectal cancer as an example].
Shiroiwa T; Tsutani K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():664-8. PubMed ID: 23513919
[No Abstract] [Full Text] [Related]
4. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
Cheon EC; Small W; Strouch MJ; Krantz SB; Rademaker A; Mulcahy MF; Benson AB; Bentrem DJ; Talamonti MS
J Surg Oncol; 2010 Oct; 102(5):539-42. PubMed ID: 20812264
[TBL] [Abstract][Full Text] [Related]
5. [Breast cancer therapy with combination of endocrine and target drugs].
Korman DB
Vopr Onkol; 2011; 57(1):14-24. PubMed ID: 21598703
[No Abstract] [Full Text] [Related]
6. [Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].
Manikhas GM; Korolenko VO; Al'-Nekhmi AA; Antimonik NIu
Vopr Onkol; 2010; 56(5):613-6. PubMed ID: 21137245
[TBL] [Abstract][Full Text] [Related]
7. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
Coriat R; Mir O; Chaussade S; Goldwasser F
Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
[No Abstract] [Full Text] [Related]
8. [Issues of molecular targeted therapies in combination with chemotherapy in metastatic colorectal cancer].
Asayama M; Kadowaki S; Yamaguchi K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():464-71. PubMed ID: 22214005
[No Abstract] [Full Text] [Related]
9. Bevacizumab in colorectal cancer.
Sonpavde G
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15483292
[No Abstract] [Full Text] [Related]
10. Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer.
Scheithauer W; Schmiegel W
Onkologie; 2009 Jul; 32(7):431-9. PubMed ID: 19556824
[TBL] [Abstract][Full Text] [Related]
11. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
12. Managing bevacizumab-related toxicities in patients with colorectal cancer.
Saif MW
J Support Oncol; 2009; 7(6):245-51. PubMed ID: 20380333
[No Abstract] [Full Text] [Related]
13. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.
Petrelli NJ
J Clin Oncol; 2009 Apr; 27(11):1917; author reply 1918. PubMed ID: 19255304
[No Abstract] [Full Text] [Related]
15. Progress with biological agents in metastatic colorectal cancer leads to many challenges.
Van Cutsem E
J Clin Oncol; 2006 Jul; 24(21):3325-7. PubMed ID: 16849745
[No Abstract] [Full Text] [Related]
16. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
Tyagi P
Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
[No Abstract] [Full Text] [Related]
17. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
Krämer I; Lipp HP
Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
[TBL] [Abstract][Full Text] [Related]
18. Current role of bevacizumab in colorectal cancer.
Saltz L
Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
[No Abstract] [Full Text] [Related]
19. Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer.
Benson AB
Clin Adv Hematol Oncol; 2006 Oct; 4(10):747. PubMed ID: 17111559
[No Abstract] [Full Text] [Related]
20. When does the presence of the target predict response to the targeted agent?
Bergsland EK
J Clin Oncol; 2006 Jan; 24(2):213-6. PubMed ID: 16365177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
